Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31301903 | 0.98 | STING1 (0.36) | GRM4STING1HDAC1HDAC2HDAC6 | |
| SCHEMBL23223933 | 0.87 | EPHX2 (0.37) | GRM4STING1HDAC1HDAC2HDAC6 | |
| SCHEMBL328633 | 0.86 | STING1 (0.36) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL16334546 | 0.86 | STING1 (0.36) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL23223961 | 0.85 | EPHX2 (0.39) | GRM4STING1HDAC1HDAC2HDAC6 | |
| SCHEMBL28026420 | 0.84 | STING1 (0.36) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL19001556 | 0.83 | STING1 (0.31) | STING1 | |
| SCHEMBL1263504 | 0.82 | HDAC1 (0.34) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL16327485 | 0.81 | HDAC6 (0.37) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL10014001 | 0.81 | HDAC6 (0.37) | STING1HDAC1HDAC2HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4230264-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2026-01-28 | — | — | EP | disclosed |
| EP-4217356-B1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-14 | — | — | EP | disclosed |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-04-24 | — | — | US | disclosed |
| US-20250057770-A1 | Monomethylfumarate Prodrug Compositions | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-02-20 | — | — | US | disclosed |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2024-09-03 | — | — | US | disclosed |
| US-20240101554-A1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-28 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-4230264-A2 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2023-08-23 | — | — | EP | disclosed |
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| EP-1401808-B1 | GPE ANALOGS AND PEPTIDOMIMETICS | NEUREN PHARMACEUTICALS LTD (NZ) | 2009-07-08 | — | — | EP | disclosed |
| US-7041314-B2 | GPE analogs and peptidominetics | NEUREN PHARMACEUTICALS LTD. (NZ) | 2006-05-09 | — | — | US | disclosed |
| EP-1401808-A4 | GPE ANALOGS AND PEPTIDOMIMETICS | NEURONZ LTD (NZ) | 2004-08-25 | — | — | EP | disclosed |
| EP-1401808-A2 | GPE ANALOGS AND PEPTIDOMIMETICS | Neuronz Limited (NZ) | 2004-03-31 | — | — | EP | disclosed |
| US-20030055004-A1 | GPE analogs and peptidominetics | NEUREN PHARMACEUTICALS LIMITED (AU) | 2003-03-20 | — | — | US | disclosed |
| WO-2002094856-A2 | GPE ANALOGS AND PEPTIDOMIMETICS | NEURONZ LIMITED (NZ) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | GRM4 3044/4885STING1 4636/4885HDAC1 189/4885 |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | GRM4 3044/4885STING1 4636/4885HDAC1 189/4885 |
| US-20030055004-A1 | GPE analogs and peptidominetics | GLUL, GCG, BAD | GRM4 43/4885STING1 1625/4885HDAC1 4540/4885 |
| US-20250057770-A1 | Monomethylfumarate Prodrug Compositions | DHFR, FPGS, G6PD | GRM4 316/4885STING1 4181/4885HDAC1 685/4885 |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | GRM4 3044/4885STING1 4636/4885HDAC1 189/4885 |
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | CACNA1B, SCN1A, CACNA1I | GRM4 756/4885STING1 3342/4885HDAC1 149/4885 |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | GRM4 3044/4885STING1 4636/4885HDAC1 189/4885 |
| US-20240101554-A1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | CDK7, CDK9, CDK1 | GRM4 3918/4885STING1 4395/4885HDAC1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.